CONTEXT: There has been much speculation as to whether defects in glucagon-like peptide-1 (GLP-1) secretion play a role in the pathogenesis of type 2 diabetes and the progression from normal glucose tolerance to prediabetes and diabetes. OBJECTIVE: Our objective was to determine whether fasting and postchallenge concentrations of active and total GLP-1 decrease as glucose tolerance and insulin secretion worsen across the spectrum of prediabetes. DESIGN: This was a cross-sectional study. SETTING: The study was performed in the clinical research unit of an academic medical center. PARTICIPANTS: Participants included 165 subjects with a fasting glucose below 7.0 mmol/liter and not taking medications known to affect gastrointestinal motility or glucose metabolism. INTERVENTION: Intervention included a 2-h, 75-g oral glucose tolerance test with insulin, C-peptide, glucagon, and GLP-1 measurements at seven time points. MAIN OUTCOME MEASURE: We evaluated the association of integrated, incremental active, and total GLP-1 concentrations with integrated, incremental glucose response to 75 g oral glucose. RESULTS: After accounting for covariates, there was no evidence of a relationship of incremental glucose concentrations after oral glucose tolerance test with active and total GLP-1 (r(s) = -0.16 and P = 0.14, and r(s) = 0.00 and P > 0.9, respectively). There also was no association of GLP-1 concentrations with insulin secretion and action. CONCLUSIONS: The lack of association of GLP-1 concentrations with glucose tolerance status and with insulin secretion and action in a cohort encompassing the full spectrum of prediabetes strongly argues against a significant contribution of defects in GLP-1 secretion to the pathogenesis of prediabetes.
CONTEXT: There has been much speculation as to whether defects in glucagon-like peptide-1 (GLP-1) secretion play a role in the pathogenesis of type 2 diabetes and the progression from normal glucose tolerance to prediabetes and diabetes. OBJECTIVE: Our objective was to determine whether fasting and postchallenge concentrations of active and total GLP-1 decrease as glucose tolerance and insulin secretion worsen across the spectrum of prediabetes. DESIGN: This was a cross-sectional study. SETTING: The study was performed in the clinical research unit of an academic medical center. PARTICIPANTS: Participants included 165 subjects with a fasting glucose below 7.0 mmol/liter and not taking medications known to affect gastrointestinal motility or glucose metabolism. INTERVENTION: Intervention included a 2-h, 75-g oral glucose tolerance test with insulin, C-peptide, glucagon, and GLP-1 measurements at seven time points. MAIN OUTCOME MEASURE: We evaluated the association of integrated, incremental active, and total GLP-1 concentrations with integrated, incremental glucose response to 75 g oral glucose. RESULTS: After accounting for covariates, there was no evidence of a relationship of incremental glucose concentrations after oral glucose tolerance test with active and total GLP-1 (r(s) = -0.16 and P = 0.14, and r(s) = 0.00 and P > 0.9, respectively). There also was no association of GLP-1 concentrations with insulin secretion and action. CONCLUSIONS: The lack of association of GLP-1 concentrations with glucose tolerance status and with insulin secretion and action in a cohort encompassing the full spectrum of prediabetes strongly argues against a significant contribution of defects in GLP-1 secretion to the pathogenesis of prediabetes.
Authors: Torsten P Vahl; Breay W Paty; Bradley D Fuller; Ronald L Prigeon; David A D'Alessio Journal: J Clin Endocrinol Metab Date: 2003-04 Impact factor: 5.958
Authors: M B Toft-Nielsen; M B Damholt; S Madsbad; L M Hilsted; T E Hughes; B K Michelsen; J J Holst Journal: J Clin Endocrinol Metab Date: 2001-08 Impact factor: 5.958
Authors: Anu Sharma; Ron T Varghese; Meera Shah; Chiara Dalla Man; Claudio Cobelli; Robert A Rizza; Kent R Bailey; Adrian Vella Journal: J Clin Endocrinol Metab Date: 2018-01-01 Impact factor: 5.958
Authors: Hartmut Ruetten; Mathias Gebauer; Ralph H Raymond; Roberto A Calle; Claudio Cobelli; Atalanta Ghosh; R Paul Robertson; Sudha S Shankar; Myrlene A Staten; Darko Stefanovski; Adrian Vella; Kathryn Wright; David A Fryburg Journal: Metab Syndr Relat Disord Date: 2018-08-17 Impact factor: 1.894
Authors: Andrew D Biancolin; Hyerin Jeong; Kimberly W Y Mak; Zixuan Yuan; Patricia L Brubaker Journal: Endocrinology Date: 2022-09-01 Impact factor: 5.051
Authors: Sharmila C Subaran; Matthew A Sauder; Weidong Chai; Linda A Jahn; Dale E Fowler; Kevin W Aylor; Ananda Basu; Zhenqi Liu Journal: Clin Sci (Lond) Date: 2014-08 Impact factor: 6.124
Authors: Sara F Michaliszyn; Andrea Mari; SoJung Lee; Fida Bacha; Hala Tfayli; Lama Farchoukh; Ele Ferrannini; Silva Arslanian Journal: Diabetes Date: 2014-06-19 Impact factor: 9.461